ToolGen Ramps Up CRISPR IP Monetization
South Korean biotech firm ToolGen announced it is entering a "harvest season" for its global intellectual property by appointing litigation expert Dave Koo as its new Chief Legal Officer. The move signals a more aggressive strategy to monetize its CRISPR gene-editing patents, which could reshape patent pool dynamics and licensing trends in the biotechnology sector.
- The intellectual property landscape for CRISPR-Cas9 is fiercely contested among key players including the Broad Institute of MIT and Harvard, the University of California (UC), and ToolGen. The disputes largely center on who first invented the use of the gene-editing technology in eukaryotic cells, which are crucial for developing human therapeutics. - In the United States, which operated under a "first-to-invent" patent system until 2013, ToolGen is engaged in patent interference proceedings with both the Broad Institute and the UC group (CVC). The U.S. Patent Trial and Appeal Board (PTAB) has designated ToolGen as the "senior party" in these proceedings, giving it a favorable position as it places the burden of proof on the other parties. - Globally, the patent rights are fragmented. For instance, in Japan, the CVC group recently won a significant legal victory against a challenge from ToolGen, strengthening its position in Asia. Meanwhile, in Australia, a ToolGen patent application was successfully opposed, leading to a Federal Court upholding the decision against ToolGen's priority claim. - The complexity and fragmentation of CRISPR patents have led to a situation where companies may need to obtain licenses from multiple entities—including CVC, the Broad Institute, and ToolGen—to ensure global freedom to operate and avoid litigation. This has prompted discussions about forming a patent pool to streamline licensing, similar to models used in the telecommunications sector, though a widely adopted solution has yet to emerge. - ToolGen has initiated patent infringement lawsuits in Europe and the U.S. against Vertex Pharmaceuticals and its partners concerning their product Casgevy, the first approved CRISPR-based therapy. This legal action followed the granting of key patents to ToolGen in Europe and the U.S. related to the direct delivery of the CRISPR-Cas9 complex into cells. - The ongoing legal battles create significant uncertainty for commercial development. Key patents may even expire before all disputes are resolved, and the landscape is further complicated by the development of newer CRISPR systems like Cas12 and Cas13.
